Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target hoisted by equities researchers at UBS Group from $162.00 to $176.00 in a research note issued to investors on ...

Equities research analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for Neurocrine Biosciences in ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.

UBS raised the firm’s price target on Neurocrine (NBIX) to $176 from $162 and keeps a Buy rating on the shares. The firm expects Neurocrine to ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Neurocrine Biosciences begins phase 3 registrational study of osavampator as an adjunctive therapy to treat major depressive disorder: San Diego Wednesday, January 29, 2025, 18:00 ...

Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...

Mizuho Securities analyst Uy Ear has maintained their neutral stance on NBIX stock, giving a Hold rating on January 21.Invest with Confidence: ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...